Merck KGaA at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

Merck KGaA takes part in 2 sessions at ESMO 2026 in Madrid, and exhibits at Booth 1034. Its program spans new treatment developments in metastatic colorectal cancer. It also covers the changing management of rare desmoid tumours in clinical practice.

OrganizationESMO 2026 Attendance
merckgroup.com
Large pharmaExhibitor
German science and technology company whose healthcare business markets oncology medicines including avelumab, cetuximab and tepotinib.
Booth
Exhibiting at Booth 1034
Satellite
Sat Oct 24
13:00–14:30
Merck Healthcare KGaA - Striving for more: The cutting edge of therapeutic developments in mCRC
Sponsored session · with University of Campania Luigi Vanvitelli
Gastrointestinal cancers
Satellite
Mon Oct 26
13:00–14:30
Merck Healthcare KGaA - CARE FOR RARE: Desmoid Tumours in Clinical Practice − Shifting Strategies & Evolving Perspectives
Sponsored session · with Hospital de la Santa Creu i Sant Pau, University Medical Centre Mannheim
Sarcoma, CNS, head & neck and rare cancers

Explore the full ESMO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ESMO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Merck KGaA

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction